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Abstract 
In vitro dissolution/release tests are an indispensable tool in the drug product development, its quality 
control and the regulatory approval process. Mucosal drug delivery systems are designed to provide both 
local and systemic drug action following ocular, nasal, oromucosal, vaginal or rectal administration. They 
exhibit significant differences in formulation design, physicochemical characteristics and drug release 
properties. Therefore it is not possible to devise a single method which would be suitable for release testing 
of such versatile and complex dosage forms. Different apparatuses and techniques for in vitro release 
testing for mucosal delivery systems considering the specific conditions at the administration site are 
described. In general, compendial apparatuses and methods should be used as a first approach in method 
development when applicable. However, to assure adequate simulation of conditions in vivo, novel 
biorelevant in vitro dissolution/release methods should be developed. Equipment set up, the selection of 
dissolution media and volume, membrane type, agitation speed, temperature, and assay analysis 
technique need to be carefully defined based on mucosal drug delivery system characteristics. All those 
parameters depend on the delivery system and physiological conditions at the site of application and may 
vary in a wide range, which will be discussed in details. 
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Introduction 
The drug dissolution/release test is a key test of dosage form performance both during formulation 
development as well as for quality control purposes. For majority of mucosal drug delivery systems (i.e. 
formulations aimed to provide local and/or systemic drug action via nasal, ocular, oral, rectal and vaginal 
mucosa) the methods and apparatuses for dissolution/release testing are not standardized and described 
in pharmacopoeial monographs, indicating the need for further development and systematisation of the 
currently used methods [1].  
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It should be noted that the terms drug dissolution and drug release are often not appropriately 
distinguished in the literature and even in regulatory documents. The drug dissolution process refers to all 
formulations in which the drug is initially present in the solid state and encompasses 5 major mass 
transport steps: (i) the wetting of the particle surface with water; (ii) breakdown of solid state bonds in 
drug particle; (iii) solvation of the individualized species such as ions or molecules; (iv) their diffusion 
through the liquid unstirred boundary layer and (v) convection within the well-stirred bulk fluid. If drug 
dissolution process is the rate-limiting step in the overall release process, than the terms drug dissolution 
and drug release can be considered as synonyms. In all other cases, drug release is the more appropriate 
term. In fact, the drug release is a more complex phenomenon, where drug dissolution is just one of its 
steps. Upon the contact with the aqueous dissolution medium, water penetrates into the matrix of the 
delivery system and dissolves the drug. The dissolved drug species subsequently diffuse out of the matrix 
of the delivery system due to concentration gradient. Additionally, the matrix of the delivery system might 
also undergo several changes such as swelling and consequent dissolution in the aqueous medium, all 
contributing to the overall drug release process [2,3]. Considering the complexity of mucosal delivery 
systems, often containing nanoparticulate carriers included in soluble or insoluble matrices, in vitro drug 
release seems to be the appropriate term when describing the liberation process of the drug from such 
formulations. 
In methods listed in USP and Ph. Eur. monographs, USP Dissolution Database and FDA Dissolution 
Database (Table 1), the apparatuses traditionally used for oral formulations are also often applied for 
mucosal delivery systems. However, many noncompendial methods have been developed with intention 
to take into account the specific physiochemical properties of the formulation and the physiological 
environment at which the drug should be released. The goal is to develop a test able to provide predictive 
estimation of in vivo drug product performance, with preferably level A of in vitro-in vivo correlation (IVIVC) 
[4]. Development of noncompendial methodologies requires standardization of test parameters and 
procedures in order to ensure reproducible and reliable results. Besides the equipment set up, selection of 
the dissolution media and volume, membrane type, agitation speed, temperature, and assay analysis 
technique need to be carefully defined based on mucosal drug delivery system characteristics and 
physiological conditions at the site of application [5]. This article is aimed to provide useful guidelines and 
recommendations in this regard.  
The dissolution medium selection 
As shown in Table 1, apparatuses traditionally used for oral formulations are often applied for mucosal 
delivery systems. Generally, the relatively high volume of the dissolution medium used (500-1000 ml) and 
the hydrodynamics provided by such apparatuses is not in line with the in vivo conditions at the mucosal 
administration sites. To mimic the physiological conditions at mucosal administration sites, a low volume of 
aqueous dissolution medium in the physiological pH range should be used. Some of the commonly used 
dissolution media for mucosal delivery systems are listed in Table 2. On the other hand, sink conditions 
should be maintained. In order to achieve sink conditions for a water-insoluble active compound it may be 
necessary to add surfactants (such as Tween 80 or sodium lauryl sulphate), complexing agents (such as 
cyclodextrins) or organic solvents (ethanol, methanol etc.) into the dissolution medium [14]. If organic 
solvents need to be included in dissolution medium, they have to be compatible with the formulation, and 
their concentration needs to be adjusted not to disrupt the formulation. In addition, in case of membrane 
diffusion methods, the selected solvent should also be compatible with the membrane used [15]. The most 
commonly applied temperature for oromucosal, rectal and vaginal formulations testing is 37 °C, while in 
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case of ocular and nasal formulations, temperature may wary between 32-34 and 33-37 °C, respectively 
[3].  
Table 1. Apparatuses used/recommended for in vitro release testing of mucosal formulations according to 
monographs and methods published by USP, Ph. Eur. and FDA. Reprinted from ref. [3] with permission of Elsevier. 
Formulation type Apparatus Reference 
Semisolid dosage forms  
(creams, gels, ointments, 
lotions) 
Vertical diffusion cell [6] 
Immersion cell [6] 
Flow through cell with adapter for semisolid dosage forms [6] 
Paddle apparatus [7] 
Oral, buccal and 
sublingual films 
Paddle over disk apparatus  [7–10] 
Basket apparatus (small-volume configuration) [7,8] 
Sublingual and buccal 
tablets 
Paddle apparatus (standard or small-volume configuration) [7,8,11]  
Basket apparatus (standard or small-volume configuration) [7,8] 
Lozenges Basket apparatus [7,8] 
Paddle apparatus [7,8,11] 
Reciprocating cylinder [7,8] 
Medicated chewing gums Dissolution apparatus for chewing gums [7,8,12] 
Suppositories 
(hydrophilic) 
Paddle apparatus [7,8,11] 
Basket apparatus (standard or Palmieri type basket) [7,8] 
Flow-through cell [8] 
Suppositories (lipophilic) Dual chamber flow-through cell [8,13] 
Vaginal tablets and 
vaginal inserts 
Paddle apparatus [7,8] 
Basket apparatus [7,8,11] 
Vaginal rings Incubator shaker [7] 
Mucosal suspensions Paddle apparatus (standard or small-volume configuration) [7,8] 
Mucosal emulsions Paddle apparatus [8] 
Vertical diffusion cell [8] 
Ocular systems Reciprocating shaker [11] 
Periodontal systems Tube rotator [11] 
Table 2. Some frequently used dissolution media for in vitro drug release testing of mucosal drug delivery systems. 
Reprinted from ref. [3] with permission of Elsevier. 
Medium Composition pH Reference 
Simulated tear fluid 2.18 g NaHCO3, 6.78 g NaCl, 0.063 g CaCl2, 1.38 g KCl and 








electrolyte solution  
7.45 g NaCl, 1.29 g KCl, 0.32 CaCl2x2H2O and distilled water up 




0.8 g NaCl, 3.0 g KCl, 0.45 g CaCl2 and distilled water up to 
1000 ml 
6.8 [19] 
Nasal fluid simulant  7.13 g NaCl, 2.98 g KCl, 2.14 g NaH2PO4xH20, 1.21 g 
Na2HPO4x7H2O and distilled water up to 1000 ml 
7.4 [20] 
Simulated saliva  2.38 g Na2HPO4, 0.19 g KH2PO4, 8 g NaCl and distilled water up 




1.63 g KH2PO4, 2.32 g NaCl, 0.22 g CaCl2 and distilled water up 




3.51 g NaCl, 1.4 g KOH, 0.222 g Ca(OH)2, 0.018 g bovine serum 
albumin, 2 g lactic acid, 1 g acetic acid, 0.16 g glycerol, 0.4 g 
urea, 5 g glucose and distilled water up to 1000 ml 
4.2 [23] 
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Selection of the apparatus type and setup 
Basket apparatus  
Basket apparatus (Apparatus 1; Figure 1) has been applied for the in vitro release testing of different 
mucosal delivery systems, such as nasal microparticles [24] and inserts [25] using relatively large volume 
(200-400 ml) of the dissolution medium and moderate stirring rate (50 rpm). Similar apparatus, operating 
with 250 ml of the simulated saliva and 50 or 100 rpm stirring rate were used to investigate the release of 
tizanidine hydrochloride [26] and buspirone hydrochloride [27] from freeze-dried buccal sponges/wafers. 
Those drugs are classified as Class I drugs (high solubility and permeability) according to the 
Biopharmaceutical Classification Systems (BCS) and in both cases, level A of IVIVC was obtained by such 
instrumental setup [26,27]. Basket apparatus has been also applied for the in vitro drug release testing of 
both solid and in situ gelling rectal suppositories. In latter case, the formulation was first thermostated at 
37 °C in suppository moulds to achieve solidification of the formulation prior its placing into basket [28]. 
Another approach, where a liquid suppository formulation was directly introduced into the basket covered 
with gauze, was also described [29]. Compendial monographs, USP Dissolution Database and FDA 
Dissolution Database also recommend the use of basket apparatus, both in standard and the small-volume 
configuration, for the in vitro testing of mucosal delivery systems (Table 1).  
. 
Figure 1. Schematic representation of the basket apparatus (Apparatus 1). Reprinted from ref. [3] with 
permission of Elsevier. 
Paddle apparatus and modifications 
Conventional paddle apparatus (Apparatus 2; Figure 2a) with 900 ml of the dissolution media stirred at 
50 rpm has been occasionally used for the in vitro release testing from buccal tablets [30], sublingual 
formulations [31], vaginal tablets [32] and self-microemulsifying rectal suppositories [33]. According to the 
monographs and methods published by USP, Ph. Eur. and FDA (Table 1), the paddle apparatus is used for a 
variety of mucosal drug delivery systems. However, the general intention of the researchers in the field is 
to reduce the volume of the dissolution medium applied [34,35]. In cases where the volume is significantly 
reduced to only 10-25 mL, the agitation is performed by the use of shaking incubators. Using such 
apparatus, level A IVIVC with correlation coefficient of 0.909 was obtained for carbamazepine release from 
buccal multi-composite constructs [34]. The same level of IVIVC was obtained in the case of vaginal 
NuvaRing®, using similar approach [36]. While analysing the in vitro release of buccal and sublingual films 
by paddle apparatus, a formulation is commonly attached to a glass slide with cyanoacrylate glue [37] or 
two sided adhesive tape [38] and then immersed into dissolution vessel or glued onto the inner side of the 
dissolution vessel [37]. Considering the porosity and the thickness of the formulation, the permeation of 
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the glue into the formulation could be presumed with consequent modification of the drug release 
process. In this regard, the use of metal clamps, supports with wire mesh or compendial Apparatus 5 
(paddle over disc, Figure 2b) is preferred. Furthermore, the position of the formulation (bottom or the side 
of the dissolution vessel) influences greatly on the observed in vitro drug release kinetic, due to differences 
in hydrodynamics inside the dissolution vessel [37].  
(a)  (b)  (c)  
Figure 2. Schematic representation of the paddle apparatus (a), paddle over disc apparatus (b) and immersion 
cell in combination with the small-volume paddle apparatus (c). Reprinted from ref. [3] with permission of 
Elsevier. 
Membrane diffusion methods 
Membrane diffusion (i.e. dialysis) method is considered as one of the most convenient techniques for 
determining the drug release profiles of nano-sized drug delivery systems like nanoparticles, liposomes, 
nanosuspensions and emulsions [3,39]. The most commonly used setups are dialysis bag, flow-through 
apparatus (with a membrane-containing adapter), Franz-diffusion cell and immersion cell. The advantages 
of dialysis over other methods are in the ease of sampling and replacement of receptor media due to the 
physical separation of the formulation (by semipermeable dialysis membrane) from the receptor media. 
However, it is important to emphasize that non-critical interpretation of the obtained results can lead to 
flawed conclusions about the kinetics of drug release from the colloidal carriers [40,41] and other 
formulation types [42–46]. The presence of the drug in the receptor medium is the result of drug release 
from the carrier to the continuous phase in the donor compartment and diffusion of the drug through the 
membrane from the donor to the receptor compartment. Each of these two processes can limit the overall 
drug release rate. If diffusion through the dialysis membrane is the limiting factor, then the results 
obtained do not say much about the kinetics of the drug release from the carrier. Therefore, to account for 
the resistance of the dialysis membrane to drug diffusion and its influence on the overall drug release rate, 
an in vitro release study has to be performed with the drug solution too. Furthermore, the possibility of 
reversible binding of the released drug onto a carrier in the donor compartment must be considered, which 
may reduce the thermodynamic activity of the drug in the donor compartment and thus the diffusion rate. 
This may lead to the wrong conclusions about the extended release of the drug. Finally, it is very important 
to consider that as drug diffuses through the diffusion membrane, the ions diffuse from one compartment 
to another as well. This is of the most importance for ion activated in situ gelling systems for which the 
gelation as well as gel strength is related to the concentration of crosslinking ion such as Ca2+ [3]. 
Dialysis bag with molecular weight cut-off in range from 8 to 14 kDa is the most frequently used non-
compendial setup among membrane diffusion methods. The volume of receptor media is usually between 
20 and 100 ml and stirring conditions are ranging from 50 to 150 rpm. Using dialysis method, a good IVIVC 
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was found for gatifloxacin release from ocular inserts [47]. Level A IVIVC was also achieved for paracetamol 
release from suppository formulation using similar apparatus setup [48]. Dialysis bag is also widely used to 
study the in vitro release properties of semisolid and nanoparticulate formulations aimed for ocular, nasal 
and vaginal drug delivery [3]. In some cases, the dialysis bag is introduced to the basket of Apparatus 1 or 
attached onto the paddle of the Apparatus 2. Another setup includes the use of a glass cylinder containing 
the formulation, sealed at the bottom with the semipermeable membrane and vertically immersed into 
the dissolution medium. Such apparatus is used for in vitro release testing of rectal suppositories [49].  
The compendial flow through apparatus (Apparatus 4; Figure 3) can be used in combination with a 
membrane containing adapter. This setup is widely employed for in vitro drug release testing from ocular 
inserts [50] and contact lenses [51]. Sometimes is also used in case of semisolid dosage forms [6], 
microparticles for nasal application [52] and thermosensitive gels for buccal application [53]. This 
apparatus allows the drug release testing under physiological flow rate of the dissolution medium and 
offers ability to maintain the sink conditions while operating in an open system setup. Besides compendial, 
some self-made flow through apparatuses were also used [54]. However, the flow through method shows 
some disadvantages, including instrument cost and set-up, filter clogging, drug adsorption to the 
apparatus, problems to maintain a constant flow rate and consequent high variability in the results [39]. 
 
Figure 3. Schematic representation of the flow through cell. Reprinted from ref. [3] with permission of 
Elsevier. 
Franz-diffusion cell (i.e. vertical diffusion cell, Figure 4) was originally developed for in vitro drug release 
testing from dermal creams, ointments and gels, but nowadays is widely used to test in vitro drug release 
from various mucosal delivery systems. The formulation loaded into upper donor compartment is 
separated from the receptor medium present in the lower compartment by a semipermeable membrane. 
Franz-diffusion cell was used to assess the drug release properties from numerous formulations aimed for 
nasal application, such as thermoresponsive soluble gels [55], ion activated in situ gels [56], microparticles 
[57], nanostructured lipid carriers [58], gel containing microspheres [59], lipidic emulsomes [60], in situ 
gelling microemulsions [61] and solid lipid nanoparticles [62]. This method is advantageous over other 
compendial and non-compendial membrane diffusion methods particularly in case of dry powders as it 
allows them to hydrate slowly, and gel eventually, in humid environment conditions designed to be similar 
to those encountered in the nasal cavity [63]. It has been also used in case of nano sized and gelling 
ophthalmic formulations [64,65] as well as for films [66], wafers [67] and tablets [68] aimed for oromucosal 
administration. Also, in majority of the in vitro drug release studies from nanosystem-in-hydrogel type 
vaginal formulations Franz diffusion-cell method was applied [69]. The restricted volume of acceptor 
compartment is a drawback of the Franz diffusion apparatus, which might impair significantly the observed 
drug release profile, especially in the case of poorly soluble drugs.   
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Figure 4. Schematic representation of the Franz-diffusion cell. Reprinted from ref. [3] with permission of 
Elsevier. 
The immersion cell (Figure 2c), another compendial membrane diffusion method mostly used for 
semisolid preparations, was successfully applied to study the drug release kinetic from microparticles 
aimed both for nasal and dermal application [70]. 
Recently, some membrane-less diffusion methods have been reported to study the drug release from 
ocular inserts [64] and nasal in situ forming gels [20], providing the direct contact of the formulation with 
the dissolution medium. Agarose method is another membrane-less diffusion model which allows to 
monitor the release of both the released drug and liposomally associated drug in environment simulating 
the conditions presented at the vaginal site [71]. 
Sample and separate method 
Sample and separate method is simple and provides a direct approach to determine the drug release. 
Dosage form is introduced into the release medium maintained at a constant temperature and the drug 
release is assessed by sampling of the release medium at defined time, separated by filtration [72] or 
centrifugation [73] and quantified by a suitable analytical technique [3]. The volume of the receptor 
medium should be adjusted to maintain sink conditions. This approach is applicable if the drug release lasts 
much longer (in hours) than the particle separation (in minutes) process and is often used to test in vitro 
drug release from nasal micro- and nano-sized delivery systems [72,74]. As the particle size decreases, the 
difficulties of separation increase. Complete separation of nanoparticles requires ultracentrifugation or 
ultrafiltration. The application of such a strong force for particle separation may impair their integrity and 
thus affect the drug release profile. Therefore, the conditions of separation procedure should be clearly 
stated in the published results. In (ultra)filtration the adsorption of the released drug to the filter should be 
considered. Also, the particles may clog the filter pores resulting in slow filtration and limited volume of 
filtered sample. Another disadvantage of this method is the loss of drug-loaded particles due to sampling, 
thereby resulting in an incomplete drug release profile. Another important obstacle is aggregation of 
particles which may decrease the release rate. Loss in volume because of filtration during sampling and 
buffer replacement is a concern when the amount of release media is small [75]. 
Conclusions 
Mucosal drug delivery systems differ significantly in formulation design and their physicochemical and 
release characteristics. Therefore versatile in vitro release methods are currently used for their 
characterisation, considering the specific conditions at the administration site. Compendial methods are 
used as a first approach in method development whenever applicable. Further progress in this field is 
focused towards the development of novel biorelevant methods, which would be able to predict more 
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closely the in vivo performance of the formulation. 
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